Hostname: page-component-6bf8c574d5-qdpjg Total loading time: 0 Render date: 2025-02-21T04:42:22.100Z Has data issue: false hasContentIssue false
  • English
  • Français

Authors' reply

Published online by Cambridge University Press:  03 January 2018

R. Shiloh ,
Z. Zemishlany ,
D. Aizenberg  and
A. Weizman
R. Shiloh
Affiliation:
Gehah Mental Health Center, PO Box 102, Petach-Tikua 49100, Israel
Z. Zemishlany
Affiliation:
Gehah Mental Health Center, PO Box 102, Petach-Tikua 49100, Israel
D. Aizenberg
Affiliation:
Gehah Mental Health Center, PO Box 102, Petach-Tikua 49100, Israel
A. Weizman
Affiliation:
Gehah Mental Health Center, PO Box 102, Petach-Tikua 49100, Israel
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns
Information
The British Journal of Psychiatry , Volume 172 , Issue 5 , May 1998 , pp. 450
Copyright
Copyright © 1998 The Royal College of Psychiatrists 

References

Devinsky, O., Honigfeld, G. & Patin, J. (1991) Clozapine-related seizures. Neurology, 41, 369–371.Google Scholar
Friedman, J., Ault, K. & Powchik, P. (1997) Pimozide augmentation for the treatment of schizophrenic patients who are partial responders to clozapine. Biological Psychiatry, 42, 522–523.CrossRefGoogle ScholarPubMed
Henderson, D. C. & Goff, D. C. (1996) Risperidone as an adjunct to clozapine therapy in chronic schizophrenics. Journal of Clinical Psychiatry, 57, 395–397.Google ScholarPubMed
Submit a response

eLetters

No eLetters have been published for this article.